AcquisitionsJul 31, 2026, 08:01 AM
AbbVie to Acquire Apogee Therapeutics for $10.9B; Q2 EPS $2.03
AI Summary
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, significantly deepening its immunology portfolio. The company reported strong second-quarter 2026 financial results, with diluted GAAP EPS increasing 290.4% to $2.03 and adjusted diluted EPS rising 22.9% to $3.65. Net revenues grew 10.2% to $16.990 billion, driven by robust performance in its immunology and neuroscience segments. AbbVie also updated its full-year 2026 adjusted diluted EPS guidance to $13.87 - $14.07, reflecting the dilutive impact of the Apogee acquisition, and announced several key product approvals.
Key Highlights
- To acquire Apogee Therapeutics for approximately $10.9 billion.
- Q2 diluted GAAP EPS $2.03, a 290.4% increase.
- Q2 adjusted diluted EPS $3.65, a 22.9% increase.
- Q2 net revenues $16.990 billion, a 10.2% increase.
- Immunology portfolio net revenues $8.786 billion, up 15.1%.
- Neuroscience portfolio net revenues $3.228 billion, up 20.3%.
- Updated 2026 adjusted diluted EPS guidance to $13.87 - $14.07.
- Received multiple regulatory approvals for Skyrizi, Rinvoq, Aquipta, and Decnupaz.
Price Impact
More from ABBV